Upcoming Presentation at UBS Virtual Event
MIAMI, Oct. 07, 2024 – Longeveron Inc. (NASDAQ: LGVN), a pioneering clinical stage regenerative medicine biotechnology company, is making notable strides in cellular therapies for severe and chronic health issues linked to aging. Plans are in motion for Wa'el Hashad, the Chief Executive Officer, to engage in a Fireside Chat during the UBS Virtual Organ Restoration and Cell Therapy Day, with the event scheduled for October 15, 2024.
Event Details
In a stimulating dialogue with Ash Verma, a prominent analyst specializing in SMID-cap Biotechnology and Specialty Pharma at UBS Equity Research, Wa'el Hashad will discuss critical topics related to advancements in regenerative medicine. Executives will explore innovative solutions that target life-threatening health conditions across various demographics.
About Longeveron Inc.
Longeveron operates at the forefront of biotechnology, focused on developing groundbreaking therapies that meet unfulfilled medical needs. Its lead product, Lomecel-B™, is a unique allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors. This innovative therapy aims to capitalize on several mechanisms of action, promoting vascular health, regenerative processes, reducing inflammation, and facilitating tissue repair that may be beneficial across a wide range of diseases.
Key Areas of Research
Longeveron's research efforts are directed at three primary conditions: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), and Aging-related Frailty. The development of Lomecel-B™ has garnered significant recognition from regulatory agencies, having received five distinct and crucial designations from the U.S. FDA. These include Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, alongside Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for Alzheimer's disease.
Importance of Regenerative Medicine
Regenerative medicine represents an exciting advancement within the medical field, particularly for conditions that have limited treatment options. By leveraging cellular therapies such as Lomecel-B™, Longeveron aims to improve patient outcomes and provide new hope to those suffering from debilitating diseases. The efficacy and safety of their therapies could significantly impact future treatment protocols.
Engaging with the Scientific Community
Through events like the UBS Virtual Organ Restoration and Cell Therapy Day, Longeveron participates in key discussions that shape the future of medical treatment. Engaging with industry experts and medical professionals fosters collaborative efforts in advancing research and development within this dynamic sector.
Investor Relations and Communication
Longeveron maintains transparency with its stakeholders, offering valuable insights into its research endeavors and future directions. Interested parties can access the investor presentation in the "Events & Presentations" section of the Company’s website. For further inquiries, attendees are encouraged to reach out to their UBS representative to secure their participation in this exciting virtual experience.
Frequently Asked Questions
What is the focus of Longeveron Inc.?
Longeveron Inc. is dedicated to developing innovative cellular therapies for life-threatening and chronic aging-related health conditions.
When will the fireside chat take place?
The fireside chat is scheduled for October 15, 2024, from 3:00 p.m. to 3:45 p.m. ET.
What are Lomecel-B™ therapies?
Lomecel-B™ is an allogeneic medicinal signaling cell therapy that has various mechanisms for addressing health issues related to aging and chronic disease.
How has Longeveron been recognized by the FDA?
Longeveron has received crucial FDA designations, including Orphan Drug and Fast Track designations for its programs targeting HLHS and AD.
How can investors stay updated on Longeveron's progress?
Investors can access updates and presentations on Longeveron’s website and contact investor relations for more information.
